ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,561 to 2,580 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Liberal Group vs Restrictive Group: serious adverse events103 of 1,493

118 of 1,490

-1.0 points

-2.9 to 0.9

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Trivalent MRKAd5 HIV-1 Gag/Pol/Nef vs Placebo: serious adverse events19 of 1,484

17 of 1,495

0.1 points

-0.7 to 1.0

2,979NCT00095576

Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)

Arm I:Sentinel Node Resection+Conventional Axillary Dissection vs Arm II: Sentinel Node Resection Followed by Node Examination: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit276 of 1,449

200 of 1,519

5.9 points

3.2 to 8.5

2,968NCT00003830

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Liberal vs Restrictive: Sepsis129 of 1,487

157 of 1,481

-1.9 points

-4.1 to 0.2

2,968NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: Pulmonary Oedema32 of 1,487

20 of 1,481

0.8 points

-0.2 to 1.8

2,968NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: Pneumonia54 of 1,481

57 of 1,487

-0.2 points

-1.6 to 1.2

2,968NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: Anastomotic Leak35 of 1,487

49 of 1,481

-1.0 points

-2.2 to 0.2

2,968NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: Surgical Site Infection245 of 1,481

202 of 1,487

3.0 points

0.4 to 5.5

2,968NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Daprodustat vs rhEPO: deaths from any cause294 of 1,487

300 of 1,477

-0.5 points

-3.4 to 2.3

2,964NCT02879305

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

High-Dose Vaccine for Residents vs Standard-dose for Residents: deaths from any cause249 of 1,461

274 of 1,496

-1.3 points

-4.0 to 1.5

2,957NCT01720277

High Dose Influenza Vaccine in Nursing Home - Pilot Study

HD Fluzone Vaccine vs SD Fluzone Vaccine: Change in Residents' Functional Status196 of 1,461

206 of 1,496

-0.4 points

-2.8 to 2.1

2,957NCT01720277

High Dose Influenza Vaccine in Nursing Home - Pilot Study

Daprodustat vs rhEPO: serious adverse events773 of 1,482

748 of 1,474

1.4 points

-2.2 to 5.0

2,956NCT02879305

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Intervention Group vs Control Group: Overweight385 of 1,641

683 of 1,309

-28.7 points

-32.1 to -25.3

2,950NCT00554294

Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial

Daprodustat vs rhEPO: Number of Participants With at Least One BP Exacerbation Event During Study1,191 of 1,480

1,186 of 1,470

-0.2 points

-3.1 to 2.6

2,950NCT02879305

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Anastrozole vs Tamoxifen: Number of Breast Cancer Deaths3 of 1,449

3 of 1,489

0.0 points

-0.4 to 0.4

2,938NCT00072462

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Anastrozole vs Tamoxifen: Number of Participants With ER- Breast Cancer Recurrence24 of 1,449

15 of 1,489

0.6 points

-0.2 to 1.5

2,938NCT00072462

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Anastrozole vs Tamoxifen: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours103 of 1,449

120 of 1,489

-1.0 points

-2.9 to 1.0

2,938NCT00072462

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Anastrozole vs Tamoxifen: Number of Participants With ER+ Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours58 of 1,449

82 of 1,489

-1.5 points

-3.1 to 0.0

2,938NCT00072462

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Anastrozole vs Tamoxifen: Number of Non-breast Cancer Deaths59 of 1,449

65 of 1,489

-0.3 points

-1.8 to 1.2

2,938NCT00072462

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Anastrozole vs Tamoxifen: deaths from any cause62 of 1,449

69 of 1,489

-0.4 points

-1.9 to 1.2

2,938NCT00072462

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=129"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=129

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02073162-sae",
        "title": "Liberal Group vs Restrictive Group: serious adverse events",
        "summary": "103 of 1493 against 118 of 1490; risk difference -1.0 points, 95% interval -2.9 to 0.9; NCT02073162, REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery",
        "record": "/library/comparisons/NCT02073162-sae",
        "nct_id": "NCT02073162",
        "kind": "serious-adverse-events",
        "participants": 2983,
        "risk_difference": {
          "value": -0.010206017342677468,
          "lower": -0.029136665387459806,
          "upper": 0.008660030732024891
        },
        "group_1": "103 of 1,493",
        "group_2": "118 of 1,490",
        "difference": "-1.0 points",
        "interval": "-2.9 to 0.9",
        "trial_title": "REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery"
      },
      {
        "id": "NCT00095576-sae",
        "title": "Trivalent MRKAd5 HIV-1 Gag/Pol/Nef vs Placebo: serious adverse events",
        "summary": "19 of 1484 against 17 of 1495; risk difference 0.1 points, 95% interval -0.7 to 1.0; NCT00095576, Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)",
        "record": "/library/comparisons/NCT00095576-sae",
        "nct_id": "NCT00095576",
        "kind": "serious-adverse-events",
        "participants": 2979,
        "risk_difference": {
          "value": 0.001431997043153728,
          "lower": -0.006743378297861383,
          "upper": 0.009717992960848548
        },
        "group_1": "19 of 1,484",
        "group_2": "17 of 1,495",
        "difference": "0.1 points",
        "interval": "-0.7 to 1.0",
        "trial_title": "Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=130",
  "request_id": "rOlIJvVH5lyweo1k"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?